2,300 fewer last year! These 20 pharmaceutical companies have the largest number of pharmaceutical representatives in Japan

Again to the weekend, other not pushed, simple and small partners to talk about our professional affairsThe daily attention to the big mite push of the small partners know that the number of Japanese medical representatives is decreasing year by year, and according to the latest news, last year, a reduction of 2,300 people! As in previous years, the Journal of Pharmaceutical Information Express conducted a survey of the number of pharmaceutical representatives in Japan in 2020, and in the June issue of the journal listed the largest number of pharmaceutical representatives of the 20 pharmaceutical companies, the list is as follows: 58 effective lying drug companies this year, compared with 53 pharmaceutical companies last year to compare, it found that in the past year, the number of pharmaceutical representatives decreased by more than 2,300 peopleSpecifically, the annual survey is based on the number of pharmaceutical representatives of pharmaceutical companies as of 1 April, plus the number of pharmaceutical representatives to be employed in April as the number of pharmaceutical representatives of the Division in the current year, with the number of pharmaceutical companies in the year ending December last yearThis year's 53 pharmaceutical companies have 35,958 pharmaceutical representatives, down 2,315 from last year's 38,273, and because Sanofi, Bayer and Novartis have not been made public this year, these companies also have early retirement representatives, so overall, the number of people down this year is bound to be more than 2,300It's an indisputable fact that Japanese pharmaceutical representatives are decreasing year by year, and last year's survey, which was shared with small partners, was 2,500 fewer than in 2018, with the largest decrease of 400 from Astellas and 372 fewer in SanofiLooking ahead, Dami has also shared, with 3,364 fewer in four years from the 59 companies comparable from 2015 to 2018, compared with more in the last two yearsIn the past year, companies with more than 200 pharmaceutical representatives have declined: Astellas (300), Mercado (300), Birdhouse Pharmaceuticals (285), Pfizer (249), and GlaxoSmithKline (200)The decrease was mainly due to the transfer of part of Amgen, which announced on April 1 this year that it had completed its acquisition of a 49% stake in Amgen Astellas, a subsidiary of Amgen Astellas BioPharma K.K(AABP), and changed its name to Amgen K.K., which officially became amgen K.K., a wholly owned subsidiary of Amgen in Japan, after an astep to amgenCombined with the combined calculation of new and departing staff last year, the total number of new recruits and departures has decreased by 300 and is currently staffed by 1700 medical representativesIn 2019, Mercayon, BirdHouse And Pfizer all made early-retirement effortsMercado has reduced the number of people by 300 as a result of its core business transformation and currently maintains a medical representation of 1,600Bird House Pharmaceuticals, which lost 3.2 billion yen last year because of the termination of licensing rights to six anti-HIV drugs and Gilead Sciences, underwent a change in its business structure, called for early retirement in a new mid-term management plan at the beginning of the year, and even suspended its april hiringPfizer has maintained a team of more than 2,000 pharmaceutical representatives in Japan for many years, up to 3,000 at most, in many Japanese pharmaceutical companies have been ranked first, but since 2018 gradually downsize the number of representatives, in 2019, Pfizer Japan believes that the market environment changes beyond expectations, but also resolutely carry out cost structure reform, the implementation of early retirement plan, according to Japanese media reports at the time, the number of people raised in about 200 people, raised mainly for 500 people However, according to the current survey results, Pfizer Japan's current team of pharmaceutical representatives is only 1971 peopleThere are four companies with a reduction of 100 to 200 people: Xinghe (175), Sino-foreign Pharmaceuticals (137), Sumitomo Pharmaceuticals (135), Takeda Pharmaceuticals (100), of which Xinghe has changed from 909 to 734 from 909 before the merger, and the number of people currently at 985, as well as the number of people represented by Sumitonic Pharmaceuticals, another Japanese pharmaceutical company, has dropped to less than 985Due to the outbreak, since February this year, Japanese pharmaceutical representatives have been working from home, stop visiting medical institutions, digital promotion activities instead, has not yet fully resumed offline activities, on Tuesday, Pfizer Japan announced again, in response to the outbreak, to avoid infection, from June 1, all employees in Japan, including pharmaceutical representatives continue to work at home, do not visit medical institutions and distributorsSo the number of medical representatives this year may have a bigger impact.